Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation

Status Not yet recruiting

Clinical Trial Summary

Modified Right Lobe Graft(MRLG) is one of the most common used graft in liver transplantation .Anterior sector of allograft in MRLG usually congested to decrease this congestion tributaries of middle hepatic vein should be drained to inferior vena cava .

There are too many techniques available for this drainage using either cryopreserved or synthetic graft for vascular anastomosis .In this study we will compare between two different technique using ringed synthetic polytetrafluoroethylene (PTFE) graft to assess outflow adequacy in both technique.

Clinical Trial Description

Comparative, prospective, observational, two-groups study. group 1 : Middle Hepatic Vein(MHV) will reconstructed by fashioning a PTFE graft of suitable size positioned parallel to the cut surface of the Modified Right Lobe Graft.This position theoretically make the PTFE graft in a position similar to MHV.Any vein >4mm will be connected end to side fashion to the PTFE graft.The distal end of the PTFE graft will be closed by hemolock just distal to segment 5 vein .The proximal end of PTFE graft will be anastomosed to the recipient MHV orifice or MHV/lift orifice group 2: The end of segment 5 vein will be anastomosed to the end of suitable size PTFE graft which will be anastomosed to Inferior Vena Cava (IVC) directly and The end of segment 8 vein will be anastomosed to the end of suitable size PTFE graft which will be anastomosed to MHV or MHV/Lift orifice directly.the study will not be randomized .All operation will be done by tha same team .Choice of technique at surgeon discretion .Outflow adequecy will be assessed by Doppler Ultrasound intraoperatively and daily for 5 day once per week for 4 week and ,2,3,6,month.Progressive diminished flow or absent flow both will be considered as graft not patent .Markers of venous congestion will be considered as secondary outcome measure. ;

Study Design

Related Conditions & MeSH terms

Liver Transplant

Clinical Trial Details

NCT number	NCT03666689
Study type	Observational
Source	Assiut University
Contact	Ahmed Abdalla, master
Phone	+2001018942253
Email	draboabdalla33@gmail.com
Status	Not yet recruiting
Phase
Start date	October 1, 2018
Completion date	May 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02798861` - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed	`NCT03527238` - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine	Phase 2
Completed	`NCT01696331` - Text Messaging for Adherence in Adolescent Liver Transplant Recipients	N/A
Recruiting	`NCT05051605` - Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
Recruiting	`NCT05940857` - Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
Completed	`NCT01598987` - Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.	Phase 3
Active, not recruiting	`NCT05074160` - OCS Liver Perfusion (OLP) Post-Approval Registry
Completed	`NCT05087550` - Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
Recruiting	`NCT04836923` - LIFT Intervention in Liver Transplant Candidates	N/A
Not yet recruiting	`NCT06088758` - Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool	N/A
Terminated	`NCT01230502` - Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation	N/A
Completed	`NCT00171509` - Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients	Phase 4
Not yet recruiting	`NCT06254248` - Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma	Phase 2
Recruiting	`NCT06075745` - Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates	Phase 2
Not yet recruiting	`NCT06280950` - Expanding Liver Transplant Immunosuppression Minimization Via Everolimus	Phase 2
Completed	`NCT02057484` - A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
Active, not recruiting	`NCT03577431` - Liver Transplantation With Tregs at MGH	Phase 1/Phase 2
Recruiting	`NCT06342557` - Transitional ePRO Diary Liver
Not yet recruiting	`NCT04265157` - Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
Recruiting	`NCT02863250` - Australian and New Zealand Massive Transfusion Registry

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.